Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

MannKind's Stone-Age Technology Is Not Rolling Off The Shelves

2018-03-21 seekingalpha
Technosphere being a non-participant in 1,350 active inhalation clinical trials over the last four years does not bode well for MannKind. (70-0)

MannKind Scripts Dip As Company Works On Debt Structure

2018-03-19 seekingalpha
MannKind (MNKD) shareholders have seen an interesting week. The company has begun its use of shares as currency on debt, while also seeing script sales of Afrezza dip below 400. The dilution moves by MannKind are strategic, but investors need to be aware and cognizant of the level of dilution happening. Just after the reverse split in 2017, the outstanding share count was 95 million; with this latest move, the outstanding share count is now over 125 million. (67-0)

Options Traders Expect Huge Moves in MannKind (MNKD) Stock

2018-03-16 zacks
Investors in MannKind Corporation (MNKD - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 18, 2018 $10 Call had some of the highest implied volatility of all equity options today. (67-0)

MannKind: A Rebuttal For The Gander

2018-03-12 seekingalpha
Why the gander made me return after stating I had written my last planned article dealing with MannKind. (67-2)

Major Biotechs: Tough Call for Short Sellers

2018-03-12 247wallst
The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. (287-0)

MNKD / MannKind Corp. FORM 8-K (Current Report)


MannKind - Afrezza Scripts Remain Flat; Cash Has Better Options Now

2018-03-03 seekingalpha
MannKind (MNKD) investors have seen a busy week with this company. Management announced its earnings on Tuesday, on Wednesday the company announced a new ATM facility with a new and more visible brokerage house, and on Thursday the company announced that it is initiating a phase 1 clinical trial on an investigational drug for the treatment of pulmonary arterial hypertension. Friday is Afrezza scripts day, so here we are with the closing report for the week. (75-0)

MannKind Begins Phase 1 Clinical Trial On PAH Drug

2018-03-02 seekingalpha
MannKind (MNKD) announced today that it is launching its phase 1 clinical trial for an investigational drug used to treat pulmonary arterial hypertension (PAH). MannKind plans to use the existing drug, treprostinil, in conjunction with Technosphere to deliver a dry powder inhaled treatment. MannKind has dubbed the investigational drug as Trep-T. The primary objective of the Phase 1 clinical study is to investigate the safety, tolerability, and pharmacokinetics of Trep-T in healthy volunteers after dosing by oral inhalation. (67-0)

Your Daily Pharma Scoop: Celgene Setback, Valeant Results, Synergy Sells Rights

2018-03-01 seekingalpha
Our Marketplace service, the Total Pharma Tracker, is going to offer a one-week free trial starting March 1. Click here to register. The offer lasts until March 7; so, you know, hurry. (555-5)

With a $7 Target Price, Is MannKind at Risk of Bankruptcy?

2018-02-28 247wallst
MannKind Corp. (NASDAQ: MNKD) has been under fire from Wall Street for quite some time and is no stranger to the cold shoulder of analysts. Its shares did tumble in Wednesday’s session after one analyst downgraded the stock. (67-2)

MannKind Inks ATM Deal - What It Means For Cash Situation

2018-02-28 seekingalpha
Subsequent to the quarterly conference call held on Tuesday, February 27th, MannKind (MNKD) announced that it has struck a deal with Cantor Fitzgerald to act as the agent for the sale of up to $50 million worth of stock on an "At-The-Market" basis. (67-0)

Major Biotechs Continue to See a Rising Tide of Short Interest

2018-02-28 247wallst
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. (287-1)

MNKD / MannKind Corp. 424B5 (Prospectus)

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210792 PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2016) $50,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.01 par value per share, offered by this prospectus supplement and the accompanying prospectus. (67-0)

MannKind Q4 Report Highlights - What To Watch For In 2018

2018-02-28 seekingalpha
MannKind (MNKD) conducted its Q4 conference call after the market closed on Tuesday. The company reported a loss of $32.8 million and the equity traded down in after hours. (67-0)

MannKind's (MNKD) CEO Michael Castagna on Q4 2017 Results - Earnings Call Transcript

2018-02-28 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the MannKind Corporation 2017 Fourth Quarter and Full Year Conference Call. (Operator Instructions) As a reminder, this call is being recorded on February 27, 2018. And will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until March 13. Joining us today from MannKind our Chief Executive Officer, Michael Catania; Chief Financial Officer, Steven Binder; Chief Commercial Officer, Patrick McCauley; Chief Medical Officer, Dr. (67-0)

MNKD : MannKind Corporation Stock Analysis and Research Report

MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. Its only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the FDA on June 27, 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3 million people in the United States had diabetes in 2015. Globally, the International Diabetes Federation has estimated that approximately 415.0 million people had diabetes in 2015 and approximately 642.0 million people will have diabetes by 2040. Afrezza is a rapid-acting inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Administered at the...
Click for full article
CUSIP: 56400P201